September 11, 2019/Cancer/Research

Catch These Cleveland Clinic Cancer Center Presentations at ASTRO 2019

Join our staff at these oral and poster sessions Sept. 15-18

19-CNR-4184 QD ASTRO graphic

Cleveland Clinic Cancer Center researchers will take part in the following oral and poster presentations during the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting Sept. 15-18 at Chicago’s McCormick Place West.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Sunday, Sept. 15

Oral Presentations

Approaches to Reirradiation in Head and Neck Cancer Patients
Shlomo Koyfman, MD

10-10:15 a.m.
Room W196

Prospective Phase I Dose Escalation Study for Neoadjuvant Radiosurgery for Large Brain Metastases (Abstract #20)
Erin Murphy, MD

1:25-1:35 p.m.
Room W196

eContouring 03 – (Live SA-CME) eContouring for Oligometastatic SBRT
Gregory Videtic, MD

5:25-5:45 p.m.
Room W194

Poster Discussions

1:15-2:30 p.m.
ASTRO Innovation Hub

Ten Year Outcomes of Locoregional and Distant Recurrence for T1-2N1 Breast Cancer With or Without Post-Mastectomy Radiotherapy (Abstract #SU_2_2015)
Sarah Sittenfeld, MD

Improvement in Cardiac Dosimetry by Optimizing Heart-Sparing Breast Radiotherapy (Abstract #SU_10_2095)
Ahmad Karimi, MD

Partial Transmission Kidney Blocks to Reduce Radiation Nephropathy in Patients Receiving Myeloablative Total Body Irradiation (Abstract #SU_15_3079)
Shauna Campbell, DO

Treatment Outcomes and Patterns of Failure in High Grade Lymphoma of the Thyroid Following Combined Modality Therapy: Single Institution Series (Abstract #SU_16_3086)
Jonathan Sharrett, DO

Outcomes after SBRT for Inoperable Early Stage Lung Cancers Arising in Organ Transplant Patients (Abstract #SU_20_3115)
Christopher Fleming, MD

Technical Perspective on Novel Accelerated Partial Breast Irradiation Technique Delivered With IMRT and Online Image Guidance (Abstract #SU_3_2024)
David Majkszak

Initial Outcomes with an Image-Guided Five Fraction Accelerated Partial Breast Irradiation Regimen Delivered with IMRT (Abstract #SU_3_2025)
Elizabeth Obi, BS

Monday, Sept. 16

Oral Presentations

Malignant Transformation of Adult Low Grade Glioma: Risk Factors and Outcomes in the Molecular Era (Abstract #1060)

Martin Tom, MD

8:40-8:45 a.m.
Room W178

There will be a Meet the Expert session following this presentation with Dr. Martin Tom and Dr. Erin Murphy from 12:30-1 p.m., in the Innovation and Solution Showcase ASTRO Connect Central Nervous System – Booth #3205

Impact of Post-Prostatectomy Prostate Specific Antigen (PSA) Kinetics on Outcomes of Salvage Radiotherapy (Abstract #78)

Shauna Campbell, DO

10:55-11:05 a.m.
Room W183

Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost: Comparison of Outcomes in A Multi-Institutional Analysis of 4,086 Patients with High-Risk Prostate Cancer (Abstract #81)
Rahul Tendulkar, MD

11:25-11:35 a.m.
Room W183

Challenging Case from Dr. Adelstein (Medical Oncology)
David Adelstein, MD

11:26-11:38 a.m.
Room W181

Prostate Post-Op, Prognostic Factors and High Risk

Advertisement

Discussant
Rahul Tendulkar, MD

11:45-11:55 a.m.
Room W183

Toxicity and Efficacy Outcomes of Preoperative Pelvic Radiation Therapy in Patients with Inflammatory Bowel Disease and Rectal Cancer (Abstract #1099)
Sudha Amarnath, MD

11:50-11:55 a.m.
Room W175

Key Question 5: Use of chemotherapy, biologic, and immunotherapy agents before, during or after RT when treating cBCC and SCC
Jessica Geiger, MD

5:03-5:15 p.m.
Room W183

Quantifying Inefficiencies in Empiric Radiation Dosing: The Clinical Cost of Ignoring Biological Heterogeneity (Abstract #1112)
Jacob Scott, MD, PhD

5:15-5:20 p.m.
Room W176

Poster Discussions

10:45 a.m.-12 p.m.
ASTRO Innovation Hub

Quality of Life following Concurrent Radiotherapy and Temozolomide for Adult Patients with Low Grade Glioma (Abstract #MO_10_2238)
Deborah Park, BS

Multi-Institutional Validation of Recursive Partitioning Analysis for Overall Survival in Patients Undergoing Spine Radiosurgery for Spine Metastasis (Abstract #MO_13_2270)
Ehsan Balagamwala, MD

Influence of Treatment Package Time on Outcomes in High-Risk Oral Cavity Carcinoma in Patients receiving Adjuvant Radiation and Concurrent Systemic Therapy: A Multi-Institutional Collaborative Study (Abstract #MO_29_2924)
Neil Woody, MD, Nikhil Joshi, MD, Jessica Geiger, MD, Brian Burkey, MD, Eric Lamarre, MD, Jamie Ku, MD, Joseph Scharpf, MD, David Adelstein, MD, Shlomo Koyfman, MD

Adjuvant Radiation for Pathological N1 Patients with Oral Cavity Squamous Cell Carcinoma after Adequate Neck Dissection (Abstract #MO_30_2936)
Kailin Yang, MD, PhD

Patient Selection for De-Escalated Radiotherapy for Early-stage HPV+ Oropharynx Cancer Can be Improved by Considering Smoking Cessation: A Multi-Institution Analysis (Abstract #MO_31_2946)
James Broughman, MD, BS

Pre-Treatment Factors Predictive of Distant Recurrence after Definitive Treatment of HPV Associated Oropharyngeal Cancers(Abstract #MO_32_2957)
Christopher Fleming, MD

Factors Predictive of Overall Survival in Metastatic HPV+ Oropharyngeal Cancer: A Multi-Institutional Study (Abstract #MO_32_2958)
Christopher Fleming, MD

Factors Associated with Recurrence and Death in Patients with Aggressive Tall Cell Papillary Thyroid Cancer: A Large, Single Institution Series (Abstract #MO_36_2993)
Jonathan Sharrett, DO

Gender Differences in Clinical Presentation and Treatment Outcomes in Aggressive Tall Cell Papillary Thyroid Carcinoma in A Large, Single Institution Experience (Abstract #MO_36_2994)
Jonathan Sharrett, DO

Using Automatic Plan Consistency Check (APCC) to Reduce Errors in Treatment Plans (Abstract #MO_42_3437)
Ping Xia, PhD

Early Outcomes of Preoperative 5-fraction Radiation Therapy for Soft Tissue Sarcoma with Immediate Resection (Abstract #MO_48_3889)
Shireen Parsai, MD

Dose Escalation for Larger Brain Metastases: A Phase I Study(Abstract #MO_6_2195)
Erin Murphy, MD, Gene Barnett, MD, MBA, John Suh, MD, Alireza Mohammad Mohammadi, MD, Lilyana Angelov, MD, Glen Stevens, DO, PhD, Jennifer Yu, MD, PhD, Gennady Neyman, PhD, Samuel Chao, MD

Tuesday, Sept. 17

Oral Presentations

Head and Neck 1 – Novel Approaches in Oropharynx Cancer (Panel)
Nikhil Joshi, MD (Moderator)

8-9 a.m.
Room W190

Workshop 05 – Young Physicians’ Session (Panel)
Sudha Amarnath, MD (Moderator)

1-2:15 p.m.
Room W186

Multi-Site SBRT for Pediatric, Adolescent, and Young Adult Patients with Metastatic Sarcoma: Early Outcomes and Safety Data
Shireen Parsai, MD

Advertisement

1:20-1:25 p.m.
Room W179

A Volumetric Dosimetry Analysis of Vertebral Body Fracture Risk after Spine Stereotactic Radiosurgery (Abstract #153)
Maxwell Lee, BS

3:35-3:45 p.m.
Room W192

Targeting Metabolic Reprogramming to Radiosensitize Glioblastoma Stem Cells (Abstract #156)
Kailin Yang, MD, PhD

5:05-5:15 p.m.
Room W194

Poster Discussions

1-2:15 p.m.
ASTRO Innovation Hub

Fractionated Spine Stereotactic Body Radiotherapy for Treatment of Primary and Metastatic Sarcoma (Abstract # TU_14_3311)
Maxwell Lee, BS

Incidence and Dosimetric Impact of Minor and Observer Contouring Errors for Head and Neck (Abstract # TU_35_3729)
Bingqi Guo, PhD

Monitoring Intra-Fraction Prostate Motion Using Kv Triggered Imaging during SBRT (Abstract # TU_37_3748)
Bingqi Guo, PhD

2:45-4 p.m.
ASTRO Innovation Hub

Low Rates of Endoesophageal HDR Brachytherapy Toxicity: Long Term Results of a 3-Tube Technique in De Novo and Recurrent, Stage I, Non-surgical Patients (Abstract # TU_6_2421)
John Greskovich, MD

Downstaging of Hepatocellular Carcinoma Outside Milan Criteria Using SBRT (Abstract # TU_14_2503)
Christopher Fleming, MD

A Comparison between External Beam Radiotherapy and Low Dose-Rate Brachytherapy for Definitive Treatment of Gleason 9&10 (ISUP 5) Prostate Cancer (Abstract # TU_26_2623)
Jay Ciezki, MD

Evaluating the 2018 NCCN Classification System for Intermediate-risk Prostate Cancer Patients Undergoing External-beam Radiation Therapy (Abstract # TU_34_2704)
Timothy Smile, MD

Impact of Cribriform Pattern 4 and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy (Abstract # TU_35_2709)
Martin Tom, MD

Validation of the 2018 NCCN Prostate Cancer Risk Classification among 2,715 Patients Treated with Low Dose Rate I-125 Brachytherapy (Abstract # TU_35_2710)
Martin Tom, MD

Clinical Outcomes Among Patients with Radiorecurrent Gleason Grade Group 5 Prostate Cancer: Impact of Initial Treatment Strategy (Abstract # TU_30_2664)
Jay Ciezki, MD

Wednesday, Sept. 18

Oral Presentations

The Radiogenomic Atlas: Systematic Charting of Genetic Variants That Determine Sensitivity to Radiation (Abstract #1236)
Mohamed Abazeed, MD, PhD

8:45-8:50 a.m.
Room W192

An Image-Based Framework for Individualizing Radiotherapy Dose (Abstract #195)
Mohamed Abazeed, MD, PhD

12:15-12:25 p.m.
Room W185

Physics 11-Hardware Technologies and Treatment Delivery (Panel)
Ping Xia, PhD (Moderator)

1:15-2:30 p.m.
Room W175

Related Articles

Doctors working on MGUS screening study
March 18, 2024/Cancer/Research
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024/Cancer/Research
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024/Cancer/Research
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024/Cancer/Research
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024/Cancer/Research
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024/Cancer/Research
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024/Cancer/Research
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023/Cancer/Research
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

Ad